Forbion Capital Partners has secured €185 million for the first close of a new venture fund that will support European companies with late-stage assets. The new Forbion Growth Opportunities Fund is being supported by returning investors Pantheon, a US private equity group; KfW Capital GmbH of Germany; and the European Investment Fund, a lending agency of the EU. New investors include Eli Lilly and Co, Horizon Therapeutics Plc, Belgian Growth Fund and New Waves Investments.
